Revenue: As of FY2026 Q1, the actual value is USD 162.09 K.EPS: As of FY2026 Q1, the actual value is USD -1.28.EBIT: As of FY2026 Q1, the actual value is USD -2.105 M.60 Degrees Pharmaceuticals, Inc. operates as a single segment focused on the development and marketing of new medicines for infectious diseases .<h4>Revenue</h4>Product Revenues – net of Discounts and Rebates decreased slightly to $162,092 for the three months ended March 31, 2026, from $163,552 in the prior-year period, representing a -0.89% change, primarily due to returns associated with expiring product lots . Research Revenues significantly decreased to $0 for the three months ended March 31, 2026, from $92,731 in the prior-year period, a -100% change, due to the full utilization of the USAMMDA contract by the end of 2025 . Total Net Revenue decreased to $76,377 for the three months ended March 31, 2026, from $183,011 in the prior-year period .<h4>Sales Breakdown and Volume</h4>In Q1 2026, a U.S. pharmaceutical distributor accounted for 90% of total net product sales of Arakoda, an increase from 85% in Q1 2025 . U.S. sales volume decreased by 19%, from 1,579 16-ct box equivalents in Q1 2025 to 1,276 in Q1 2026, while discounts and rebates increased by 6% to $96,857 . Australian sales (Kodatef) to Biocelect were $15,470 in Q1 2026, up from $12,066 in Q1 2025, although sales volume decreased by 8% from 386 boxes to 354 boxes . As of March 31, 2026, Biocelect held no inventory subject to profit sharing agreements . European sales volume for Arakoda increased by 5%, from 73 boxes in Q1 2025 to 77 boxes in Q1 2026 .<h4>Operational Costs and Profitability</h4>Cost of Revenues increased to $85,715 for the three months ended March 31, 2026, from $73,272 in the prior-year period, a 16.98% increase, primarily due to higher quarterly storage costs, though per-unit costs declined . Gross Profit decreased to $76,377 for the three months ended March 31, 2026, from $90,280 in the prior-year period . Gross Margin % decreased to 47.12% for the three months ended March 31, 2026, from 55.20% in the prior-year period . Total operating expenses increased by 3.70% to $2,171,338 in Q1 2026 from $2,093,949 in Q1 2025 . Research and Development (R&amp;D) expenses decreased by -24.10% to $281,464 in Q1 2026 from $370,813 in Q1 2025, partly due to the completion of USAMMDA-funded activities, with direct trial-related costs for babesiosis trials representing 68% of total R&amp;D costs . General and Administrative (G&amp;A) expenses increased by 9.68% to $1,889,874 in Q1 2026 from $1,723,136 in Q1 2025, driven by higher sales, advertising, promotion, audit, legal, and professional fees, partially offset by lower investor outreach and stock-based compensation . Loss from Operations increased to - $2,094,961 in Q1 2026 from - $1,910,938 in Q1 2025 . The net loss attributed to 60 Degrees Pharmaceuticals, Inc. was - $2,089,214 for Q1 2026, compared to - $1,876,549 for Q1 2025 . Interest Expense decreased to - $1,389 in Q1 2026 from - $1,790 in Q1 2025 . The change in fair value of derivative liabilities resulted in a loss of - $4,567 in Q1 2026 compared to a gain of $5,105 in Q1 2025 . Other income, net, decreased to $10,762 in Q1 2026 from $30,322 in Q1 2025, primarily due to reduced interest income .<h4>Cash Flow</h4>Cash and Cash Equivalents increased to $3,337,760 as of March 31, 2026, from $1,510,065 as of December 31, 2025 . Net Cash Used in Operating Activities increased to - $2,741,559 for Q1 2026, from - $1,597,366 in Q1 2025, primarily due to higher G&amp;A expenses and vendor prepayments for API production . Net Cash Provided by Investing Activities decreased to $1,193,560 for Q1 2026, from $1,702,518 in Q1 2025, mainly from maturities of short-term investments, partially offset by fixed asset purchases and capitalized website development costs . Net Cash Provided by Financing Activities increased to $3,369,752 for Q1 2026, from $1,696,899 in Q1 2025, driven by higher net proceeds from At-the-Market (ATM) offerings .<h4>Unique Metrics and Business Developments</h4>As of March 31, 2026, one significant customer accounted for 100% of accounts receivable, and two significant customers accounted for 100% of total net product revenues (90% and 10% respectively) for Q1 2026 . Inventory write-downs for expired inventory were $3,496 in Q1 2026, compared to $35 in Q1 2025 . The company capitalized $11,440 in Q1 2026 for website enhancements . Between January 1 and January 22, 2026, the company sold 418,602 shares under the 2025 ATM Agreement, generating net proceeds of $834,705, and between March 2 and March 25, 2026, an additional 1,055,106 shares were sold under the 2026 ATM Offering, generating net proceeds of $2,535,047 . The company regained compliance with Nasdaq’s minimum bid price requirement on February 11, 2026, following a 1:4 reverse stock split effective January 20, 2026 . In Q1 2026, the company announced partnerships with Runway Health for Arakoda access and GoodRx for prescription savings . All three enrolled patients in the company’s trial were cured of babesiosis after completing the tafenoquine regimen . The company exercised an option to negotiate an exclusive license with Florida State University for castanospermine extraction and submitted a New Dietary Ingredient Notification (NDIN) to the FDA for Australian Chestnut Extract .<h4>Future Outlook and Strategy</h4>The company estimates it has sufficient funds to remain viable through mid-September 2026, assuming no additional capital raises . However, current cash and cash equivalents are insufficient to fund operating plans for the next 12 months, raising substantial doubt about its ability to continue as a going concern . Management plans to fund operations through third-party and related-party debt/advances, private placement of restricted securities, and stock issuance in subsequent offerings until profitability or a business combination is achieved, acknowledging no assurance of success in raising capital or achieving profitability .

60 Degrees Pharmaceuticals | 10-Q: FY2026 Q1 Revenue: USD 162.09 K